Skip to main content

Table 1 The circulating level of glycogen-like-peptide (GLP)-1 and echocardiography findings in five study groups of animals

From: Inhibition of dipeptidyl peptidase-IV enzyme activity protects against myocardial ischemia-reperfusion injury in rats

Variables

Group 1 (n = 8)

Group 2 (n = 8)

Group 4 (n = 8)

Group 3 (n = 8)

Group 5 (n = 8)

P value†

Serum GLP-1 level (pg/ml)*

32.6 ± 2.3a

39.1 ± 3.1b

42.1 ± 4.7b,c

45.2 ± 2.9c

48.2 ± 4.1d,c

<0.0001

Baseline echocardiography

      

LVEDd (cm)

6.8 ± 0.21

6.7 ± 0.21

6.4 ± 0.23

6.5 ± 0.24

6.5 ± 0.30

0.448

LVESd (cm)

3.4 ± 0.20

3.5 ± 0.18

3.4 ± 0.21

3.5 ± 0.20

3.4 ± 0.22

0.867

LEVF (%)

79.0 ± 1.8

79.0 ± 2.10

76.2 ± 3.70

77.0 ± 2.30

78.1 ± 2.80

0.662

Day 3 echocardiography*

      

LVEDd (cm)

6.5 ± 0.24a

6.9 ± 0.37b

6.4 ± 0.38a

6.8 ± 0.34b

6.7 ± 0.28b

0.035

LVESd (cm)

3.3 ± 0.18a

5.7 ± 0.24b

3.4 ± 0.22a

4.3 ± 0.27c

4.2 ± 0.21c

<0.001

LVEF (%)

81.0 ± 1.60a

34.0 ± 4.2b

78.0 ± 3.40a

67.0 ± 3.70c

67 ± 3.30c

<0.001

  1. Data are expressed as mean ± SD or %.
  2. Group 1 = sham control [Wide type (WT)]; Group 2 = WT + ischemia-reperfusion (IR); Group 3 = DDP4-deficiency (DDP4D); Group 4 = DDP4D + IR; Group 5 = WT + IR + sitagliptin.
  3. LVEDd = left ventricular end-diastolic dimension; LVESd = left ventricular end systolic dimension; LVEF = left ventricular ejection fraction.
  4. *indicates the blood sampling was performed at 72 h after the IR procedure.
  5. †indicates by one-way ANOVA. Different letters (a, b, c) being used for group comparison, showing significant difference (<0.05) among different groups by Bonferroni’s multiple comparison procedure.